glp-1 receptor agonists for type 2 diabetes in the Treatment of Patients with and Chronic Kidney Disease GLP-1RAs Reduce External Eating Behavior

[DOI] [PMC free article] [PubMed] [Google Scholar] 38.Zhou Z.D., Yi L.X., Wang D.Q., Lim T.M., Tan E.K

Published meta-analyses and systematic reviews indicate that both oral and injectable GLP-1 RAs delay gastric emptying, but the magnitude of this effect is similar across formulations when matched for agent and dosing schedule

Subsequent to the approval of exenatide, additional GLP-1 RAs have been FDA-approved, with differences across agents in indication for use (eg, pediatrics), route and/or intervals of administration, pharmacology, efficacy, and tolerability

Frederich R, Alexander JH, Fiodereck FT et al

Colorados Attorney General joined a lawsuit with 36 other states earlier this year, urging the FDA to enforce regulations surrounding compounded GLP-1s as well as cracking down on counterfeit versions of the drug

Tirzepatide (GLP-1 + GIP) Tirzepatide is a next-generation medication that targets two key metabolic hormonesGLP-1 and GIPto enhance weight loss, improve insulin sensitivity, and support metabolic health